Natalizumab may improve cognition and mood in multiple sclerosis (Q50593116)

From Wikidata

Jump to navigation Jump to search

scientific article

Language	Label	Description	Also known as
English	Natalizumab may improve cognition and mood in multiple sclerosis	scientific article

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

16 March 2018

http://europepmc.org/abstract/MED/22269396

Natalizumab may improve cognition and mood in multiple sclerosis (English)

1 reference

Europe PubMed Central

PubMed publication ID

16 March 2018

http://europepmc.org/abstract/MED/22269396

multiple sclerosis

0 references

author name string

C Lang

1

1 reference

Europe PubMed Central

PubMed publication ID

16 March 2018

http://europepmc.org/abstract/MED/22269396

C Reiss

2

1 reference

Europe PubMed Central

PubMed publication ID

16 March 2018

http://europepmc.org/abstract/MED/22269396

M Mäurer

3

1 reference

Europe PubMed Central

PubMed publication ID

16 March 2018

http://europepmc.org/abstract/MED/22269396

publication date

20 January 2012

1 reference

Europe PubMed Central

PubMed publication ID

16 March 2018

http://europepmc.org/abstract/MED/22269396

European Neurology

1 reference

Europe PubMed Central

PubMed publication ID

16 March 2018

http://europepmc.org/abstract/MED/22269396

67

1 reference

Europe PubMed Central

PubMed publication ID

16 March 2018

http://europepmc.org/abstract/MED/22269396

3

1 reference

Europe PubMed Central

PubMed publication ID

16 March 2018

http://europepmc.org/abstract/MED/22269396

162-166

1 reference

Europe PubMed Central

PubMed publication ID

16 March 2018

http://europepmc.org/abstract/MED/22269396

Long-term follow-up of clinical trials of multiple sclerosis therapies

1 reference

https://api.crossref.org/works/10.1159/000334722

21 January 2018

Cognitive decline in multiple sclerosis: impact of topographic lesion distribution on differential cognitive deficit patterns

1 reference

https://api.crossref.org/works/10.1159/000334722

21 January 2018

Effect of interferon-beta-1b on cognitive functions in multiple sclerosis

1 reference

https://api.crossref.org/works/10.1159/000334722

21 January 2018

Treatment options of cognitive impairment in multiple sclerosis.

1 reference

https://api.crossref.org/works/10.1159/000334722

21 January 2018

Effect of natalizumab on clinical and radiological disease activity in multiple sclerosis: a retrospective analysis of the Natalizumab Safety and Efficacy in Relapsing-Remitting Multiple Sclerosis (AFFIRM) study

1 reference

https://api.crossref.org/works/10.1159/000334722

21 January 2018

Cognitive impairment in multiple sclerosis

1 reference

https://api.crossref.org/works/10.1159/000334722

21 January 2018

Evaluation of the symbol digit modalities test (SDMT) and MS neuropsychological screening questionnaire (MSNQ) in natalizumab-treated MS patients over 48 weeks

1 reference

https://api.crossref.org/works/10.1159/000334722

21 January 2018

The effect of natalizumab on cognitive function in patients with relapsing-remitting multiple sclerosis: preliminary results of a 1-year follow-up study

1 reference

https://api.crossref.org/works/10.1159/000334722

21 January 2018

Identifiers

10.1159/000334722

1 reference

Europe PubMed Central

PubMed publication ID

16 March 2018

http://europepmc.org/abstract/MED/22269396

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

16 March 2018

http://europepmc.org/abstract/MED/22269396

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q50593116&oldid=2254047813"